Autor: |
Usama E. Abuelhassan, Medhat Elnamaky, Abdulaziz Alfifi, Sultan K. Kadasah, Mohammed A. Alshehri, Haneen A. Alasiri, Salihah Y. Al-Mani, Ali S. Kadasah, Abdullah Musleh, Fawwaz A. Alshafa, Muhammad S. S. Qureshi, Abdulmohsen Y. Assiri, Abdulrahman I. Falqi, Bader I. Asiri, Haider M. O. Ahmed, Saleem Alshehri, Fasih U. Rahman, Muhammad Amir Qureshi, Omar Abdelwahab, Sherif Mohamed, Ahmed R. I. Ali, Saad M. A. Alqahtani, Abdelrahman M. Abdalla |
Jazyk: |
angličtina |
Rok vydání: |
2024 |
Předmět: |
|
Zdroj: |
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-8 (2024) |
Druh dokumentu: |
article |
ISSN: |
1471-2466 |
DOI: |
10.1186/s12890-024-03139-x |
Popis: |
Abstract Background This study’s purposes were to evaluate the impact of biological therapies on outcomes in patients with severe asthma (SA) and chronic rhinosinusitis (CRS) and to compare these effects among those with NP (CRSwNP) versus those without NP (CRSsNP) in the “real-world” setting in Saudi Arabian patients. Methods From March to September 2022, a retrospective observational cohort study was undertaken at the severe asthma clinics of the Armed Forces Hospital—Southern Region (AFHSR) and King Khalid University Hospital, Abha, Saudi Arabia, to delineate the effects of dupilumab therapy. Outcomes were assessed, including clinical outcomes, FEV1, and laboratory findings before and one year after dupilumab. Post-therapy effects were compared between CRSwNP and CRSsNP. Results Fifty subjects were enrolled, with a mean age of 46.56. There were 27 (54%) females and 23(46%) males. Significant improvements in clinical parameters (frequency of asthma exacerbations and hospitalizations, the use of OCs, anosmia, SNOTT-22, and the ACT), FEV1, and laboratory ones (serum IgE and eosinophilic count) were observed 6 and 12 months after using dupilumab (p |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|